Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurement

We report a patient with dysfibrinogenemia treated with purified fibrinogen concentrate who had discrepant post‐treatment laboratory values. The patient had mild bleeding symptoms and was diagnosed with dysfibrinogenemia based on fibrinogen activity of 51 mg/dl and antigen of 240 mg/dl. He was treat...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2013-03, Vol.60 (3), p.500-502
Main Authors: Franzblau, Emily B., Punzalan, Rowena C., Friedman, Kenneth D., Roy, Angshumoy, Bilen, Ozlem, Flood, Veronica H.
Format: Article
Language:English
Subjects:
Adolescent
Afibrinogenemia - drug therapy
dysfibrinogenemia
fibrinogen
Fibrinogen - analysis
Fibrinogen - metabolism
Fibrinogen - therapeutic use
genetics
Hematologic Tests - standards
Hematology
hemorrhagic disorders
Humans
Laboratories
Laboratories, Hospital
Male
Oncology
Pediatrics
thrombotic disorders
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4813-531ecfc5222192872c7020abac4682dbcde32123756959e5a833570010d76a1f3
cites cdi_FETCH-LOGICAL-c4813-531ecfc5222192872c7020abac4682dbcde32123756959e5a833570010d76a1f3
container_end_page 502
container_issue 3
container_start_page 500
container_title Pediatric blood & cancer
container_volume 60
creator Franzblau, Emily B.
Punzalan, Rowena C.
Friedman, Kenneth D.
Roy, Angshumoy
Bilen, Ozlem
Flood, Veronica H.
description We report a patient with dysfibrinogenemia treated with purified fibrinogen concentrate who had discrepant post‐treatment laboratory values. The patient had mild bleeding symptoms and was diagnosed with dysfibrinogenemia based on fibrinogen activity of 51 mg/dl and antigen of 240 mg/dl. He was treated for an adenoidectomy with purified fibrinogen concentrate (RiaSTAP®) at a dose of 70 mg/kg. A discrepancy in post‐treatment fibrinogen activity was observed between the hospital and reference laboratories. Investigation revealed differences in laboratory assay and calibration methods. Fibrinogen concentrate may be a treatment option for patients with dysfibrinogenemia, but accurate laboratory technique is critical for fibrinogen measurement. Pediatr Blood Cancer 2013; 60: 500–502. © 2012 Wiley Periodicals, Inc.
doi_str_mv 10.1002/pbc.24383
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4461026</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2865595851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4813-531ecfc5222192872c7020abac4682dbcde32123756959e5a833570010d76a1f3</originalsourceid><addsrcrecordid>eNp1kUtv1TAQRi0Eoi8W_AFkiQ1dpPUjjuMNUntVLkhVqUQrlpbjTIpLEqd2Upp_j0vaS0HqypbmzNHMfAi9peSAEsIOh8oesJyX_AXapiIXmSBUvtz8idpCOzFeJ7QgonyNthinTFGittF8GQH7Bg9TcI2DGjeuCq73V9Bj63sL_RjMCLjxAddz_FuFzhls-hq7bvBhNAm997Sm8qnBh_mpydjR3bpxxh2YOAXoknYPvWpMG-HNw7uLLj-dXKw-Z6df119WR6eZzUvKM8Ep2MYKxhhVrJTMSsKIqYzNi5LVla2BM8q4FIUSCoQpOReSEEpqWRja8F30cfEOU9VBvWzU6iG4zoRZe-P0v5Xe_dBX_lbneUHTxZLgw4Mg-JsJ4qg7Fy20renBT1FTJrkoGVM8oe__Q6_9FPq0XqIKlUuV7p6o_YWywccYoNkMQ4m-D1SnQPWfQBP77un0G_IxwQQcLsAv18L8vEmfH68eldnS4eIId5sOE37qQqY76u9na32mzi8I_7bWnP8Gzl67hA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1269479129</pqid></control><display><type>article</type><title>Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurement</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Franzblau, Emily B. ; Punzalan, Rowena C. ; Friedman, Kenneth D. ; Roy, Angshumoy ; Bilen, Ozlem ; Flood, Veronica H.</creator><creatorcontrib>Franzblau, Emily B. ; Punzalan, Rowena C. ; Friedman, Kenneth D. ; Roy, Angshumoy ; Bilen, Ozlem ; Flood, Veronica H.</creatorcontrib><description>We report a patient with dysfibrinogenemia treated with purified fibrinogen concentrate who had discrepant post‐treatment laboratory values. The patient had mild bleeding symptoms and was diagnosed with dysfibrinogenemia based on fibrinogen activity of 51 mg/dl and antigen of 240 mg/dl. He was treated for an adenoidectomy with purified fibrinogen concentrate (RiaSTAP®) at a dose of 70 mg/kg. A discrepancy in post‐treatment fibrinogen activity was observed between the hospital and reference laboratories. Investigation revealed differences in laboratory assay and calibration methods. Fibrinogen concentrate may be a treatment option for patients with dysfibrinogenemia, but accurate laboratory technique is critical for fibrinogen measurement. Pediatr Blood Cancer 2013; 60: 500–502. © 2012 Wiley Periodicals, Inc.</description><identifier>ISSN: 1545-5009</identifier><identifier>EISSN: 1545-5017</identifier><identifier>DOI: 10.1002/pbc.24383</identifier><identifier>PMID: 23129109</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adolescent ; Afibrinogenemia - drug therapy ; dysfibrinogenemia ; fibrinogen ; Fibrinogen - analysis ; Fibrinogen - metabolism ; Fibrinogen - therapeutic use ; genetics ; Hematologic Tests - standards ; Hematology ; hemorrhagic disorders ; Humans ; Laboratories ; Laboratories, Hospital ; Male ; Oncology ; Pediatrics ; thrombotic disorders</subject><ispartof>Pediatric blood &amp; cancer, 2013-03, Vol.60 (3), p.500-502</ispartof><rights>Copyright © 2012 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4813-531ecfc5222192872c7020abac4682dbcde32123756959e5a833570010d76a1f3</citedby><cites>FETCH-LOGICAL-c4813-531ecfc5222192872c7020abac4682dbcde32123756959e5a833570010d76a1f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27915,27916</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23129109$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Franzblau, Emily B.</creatorcontrib><creatorcontrib>Punzalan, Rowena C.</creatorcontrib><creatorcontrib>Friedman, Kenneth D.</creatorcontrib><creatorcontrib>Roy, Angshumoy</creatorcontrib><creatorcontrib>Bilen, Ozlem</creatorcontrib><creatorcontrib>Flood, Veronica H.</creatorcontrib><title>Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurement</title><title>Pediatric blood &amp; cancer</title><addtitle>Pediatr. Blood Cancer</addtitle><description>We report a patient with dysfibrinogenemia treated with purified fibrinogen concentrate who had discrepant post‐treatment laboratory values. The patient had mild bleeding symptoms and was diagnosed with dysfibrinogenemia based on fibrinogen activity of 51 mg/dl and antigen of 240 mg/dl. He was treated for an adenoidectomy with purified fibrinogen concentrate (RiaSTAP®) at a dose of 70 mg/kg. A discrepancy in post‐treatment fibrinogen activity was observed between the hospital and reference laboratories. Investigation revealed differences in laboratory assay and calibration methods. Fibrinogen concentrate may be a treatment option for patients with dysfibrinogenemia, but accurate laboratory technique is critical for fibrinogen measurement. Pediatr Blood Cancer 2013; 60: 500–502. © 2012 Wiley Periodicals, Inc.</description><subject>Adolescent</subject><subject>Afibrinogenemia - drug therapy</subject><subject>dysfibrinogenemia</subject><subject>fibrinogen</subject><subject>Fibrinogen - analysis</subject><subject>Fibrinogen - metabolism</subject><subject>Fibrinogen - therapeutic use</subject><subject>genetics</subject><subject>Hematologic Tests - standards</subject><subject>Hematology</subject><subject>hemorrhagic disorders</subject><subject>Humans</subject><subject>Laboratories</subject><subject>Laboratories, Hospital</subject><subject>Male</subject><subject>Oncology</subject><subject>Pediatrics</subject><subject>thrombotic disorders</subject><issn>1545-5009</issn><issn>1545-5017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp1kUtv1TAQRi0Eoi8W_AFkiQ1dpPUjjuMNUntVLkhVqUQrlpbjTIpLEqd2Upp_j0vaS0HqypbmzNHMfAi9peSAEsIOh8oesJyX_AXapiIXmSBUvtz8idpCOzFeJ7QgonyNthinTFGittF8GQH7Bg9TcI2DGjeuCq73V9Bj63sL_RjMCLjxAddz_FuFzhls-hq7bvBhNAm997Sm8qnBh_mpydjR3bpxxh2YOAXoknYPvWpMG-HNw7uLLj-dXKw-Z6df119WR6eZzUvKM8Ep2MYKxhhVrJTMSsKIqYzNi5LVla2BM8q4FIUSCoQpOReSEEpqWRja8F30cfEOU9VBvWzU6iG4zoRZe-P0v5Xe_dBX_lbneUHTxZLgw4Mg-JsJ4qg7Fy20renBT1FTJrkoGVM8oe__Q6_9FPq0XqIKlUuV7p6o_YWywccYoNkMQ4m-D1SnQPWfQBP77un0G_IxwQQcLsAv18L8vEmfH68eldnS4eIId5sOE37qQqY76u9na32mzi8I_7bWnP8Gzl67hA</recordid><startdate>201303</startdate><enddate>201303</enddate><creator>Franzblau, Emily B.</creator><creator>Punzalan, Rowena C.</creator><creator>Friedman, Kenneth D.</creator><creator>Roy, Angshumoy</creator><creator>Bilen, Ozlem</creator><creator>Flood, Veronica H.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201303</creationdate><title>Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurement</title><author>Franzblau, Emily B. ; Punzalan, Rowena C. ; Friedman, Kenneth D. ; Roy, Angshumoy ; Bilen, Ozlem ; Flood, Veronica H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4813-531ecfc5222192872c7020abac4682dbcde32123756959e5a833570010d76a1f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Afibrinogenemia - drug therapy</topic><topic>dysfibrinogenemia</topic><topic>fibrinogen</topic><topic>Fibrinogen - analysis</topic><topic>Fibrinogen - metabolism</topic><topic>Fibrinogen - therapeutic use</topic><topic>genetics</topic><topic>Hematologic Tests - standards</topic><topic>Hematology</topic><topic>hemorrhagic disorders</topic><topic>Humans</topic><topic>Laboratories</topic><topic>Laboratories, Hospital</topic><topic>Male</topic><topic>Oncology</topic><topic>Pediatrics</topic><topic>thrombotic disorders</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Franzblau, Emily B.</creatorcontrib><creatorcontrib>Punzalan, Rowena C.</creatorcontrib><creatorcontrib>Friedman, Kenneth D.</creatorcontrib><creatorcontrib>Roy, Angshumoy</creatorcontrib><creatorcontrib>Bilen, Ozlem</creatorcontrib><creatorcontrib>Flood, Veronica H.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pediatric blood &amp; cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Franzblau, Emily B.</au><au>Punzalan, Rowena C.</au><au>Friedman, Kenneth D.</au><au>Roy, Angshumoy</au><au>Bilen, Ozlem</au><au>Flood, Veronica H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurement</atitle><jtitle>Pediatric blood &amp; cancer</jtitle><addtitle>Pediatr. Blood Cancer</addtitle><date>2013-03</date><risdate>2013</risdate><volume>60</volume><issue>3</issue><spage>500</spage><epage>502</epage><pages>500-502</pages><issn>1545-5009</issn><eissn>1545-5017</eissn><abstract>We report a patient with dysfibrinogenemia treated with purified fibrinogen concentrate who had discrepant post‐treatment laboratory values. The patient had mild bleeding symptoms and was diagnosed with dysfibrinogenemia based on fibrinogen activity of 51 mg/dl and antigen of 240 mg/dl. He was treated for an adenoidectomy with purified fibrinogen concentrate (RiaSTAP®) at a dose of 70 mg/kg. A discrepancy in post‐treatment fibrinogen activity was observed between the hospital and reference laboratories. Investigation revealed differences in laboratory assay and calibration methods. Fibrinogen concentrate may be a treatment option for patients with dysfibrinogenemia, but accurate laboratory technique is critical for fibrinogen measurement. Pediatr Blood Cancer 2013; 60: 500–502. © 2012 Wiley Periodicals, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>23129109</pmid><doi>10.1002/pbc.24383</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1545-5009
ispartof Pediatric blood & cancer, 2013-03, Vol.60 (3), p.500-502
issn 1545-5009
1545-5017
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4461026
source Wiley-Blackwell Read & Publish Collection
subjects Adolescent
Afibrinogenemia - drug therapy
dysfibrinogenemia
fibrinogen
Fibrinogen - analysis
Fibrinogen - metabolism
Fibrinogen - therapeutic use
genetics
Hematologic Tests - standards
Hematology
hemorrhagic disorders
Humans
Laboratories
Laboratories, Hospital
Male
Oncology
Pediatrics
thrombotic disorders
title Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurement
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T22%3A26%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20purified%20fibrinogen%20concentrate%20for%20dysfibrinogenemia%20and%20importance%20of%20laboratory%20fibrinogen%20activity%20measurement&rft.jtitle=Pediatric%20blood%20&%20cancer&rft.au=Franzblau,%20Emily%20B.&rft.date=2013-03&rft.volume=60&rft.issue=3&rft.spage=500&rft.epage=502&rft.pages=500-502&rft.issn=1545-5009&rft.eissn=1545-5017&rft_id=info:doi/10.1002/pbc.24383&rft_dat=%3Cproquest_pubme%3E2865595851%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4813-531ecfc5222192872c7020abac4682dbcde32123756959e5a833570010d76a1f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1269479129&rft_id=info:pmid/23129109&rfr_iscdi=true